NCT05769751View on ClinicalTrials.gov

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

CompletedOBSERVATIONAL
Enrollment

865

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

July 25, 2023

Study Completion Date

July 25, 2023

Conditions
HER2-positive Breast Cancer
Interventions
OTHER

Electronic medical record and hospital information system or other available resources

This is a non-interventional study. No study medication will be provided to the participants.

Trial Locations (5)

31002

Zhejiang Cancer Hospital, Hangzhou

110042

Liaoning Cancer Hospital, Shenyang

250117

Affiliated Cancer Hospital of Shandong First Medical University, Jinan

300060

Tianjin Medical University Cancer Institute & Hospital, Tianjin

510060

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT05769751 - A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter